Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
6-phosphogluconate dehydrogenase is the second dehydrogenase in the pentose phosphate shunt.
Showing 10 out of 19 products:
identified that 6-phosphogluconate dehydrogenase (6PGD) is critically involved in the development of anaplastic thyroid cancer (ATC (show SRPK1 Proteins)) resistance to doxorubicin. 6PGD inhibition disrupts metabolic reprogramming in doxorubicin-resistant ATC (show SRPK1 Proteins) cells.
Studies indicate link between the 6-phosphogluconate dehydrogenase, oxidative pentose phosphate pathway (PPP) and lipogenesis through Ru-5-P-dependent inhibition of serine/threonine protein kinase LKB1 (show STK11 Proteins)-AMPK (show PRKAA1 Proteins) signalling.
copy number gain of the PGD gene was consistently identified in cervical cancers but not in the normal tissues
Results show that 6PGD activity is upregulated with increased lysine acetylation in primary leukemia cells from human patients, providing mechanistic insights into 6PGD upregulation in cancer cells.
Expression of 6PGD positively correlates with advancing stage of lung carcinoma. Knockdown of 6PGD by shRNA potently inhibits c-Met tyrosine phosphorylation.
Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence
Data suggest that the affinity of Nox2 (show CYBB Proteins) for NADPH (show NQO1 Proteins) is increased in the presence of 6PGDH on cell stimulation.
Hsa (show CD24 Proteins)-miR (show MLXIP Proteins)-132 and -212 were negatively correlated with PGD in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders.
Taken together, these data suggest that ADD1/SREBP1c (show SREBF1 Proteins) is a key transcription factor for 6PGDH gene expression and would coordinate glucose metabolism and lipogenesis for energy homeostasis.
6-phosphogluconate dehydrogenase is the second dehydrogenase in the pentose phosphate shunt. Deficiency of this enzyme is generally asymptomatic, and the inheritance of this disorder is autosomal dominant. Hemolysis results from combined deficiency of 6-phosphogluconate dehydrogenase and 6-phosphogluconolactonase suggesting a synergism of the two enzymopathies.
6-phosphogluconate dehydrogenase, decarboxylating
, 6-phosphogluconate dehydrogenase
, NADP-6 phosphogluconate dehydrogenase
, phosphogluconate dehydrogenase
, 6-phosphogluconate dehydrogenase (decarboxylating)
, 6-phosphogluconate dehydrogenase, decarboxylating-like